In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., Its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 1, 1999, Pages 90-95

  Edelstein, Paul H ^a,b   Edelstein, Martha A C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; ERYTHROMYCIN; HMR 3004; KETOLIDE; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RU 6647; TELITHROMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; EXPERIMENTAL INFECTION; GUINEA PIG; INTRAPERITONEAL DRUG ADMINISTRATION; LEGIONELLA PNEUMOPHILA; LEGIONNAIRE DISEASE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION;

EID: 0032906803     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.1.90     Document Type: Article

References (34)

1. Agouridas, C., A. Bonnefoy, and J. F. Chantot. 1995. In vitro antibacterial activity of RU 004, a novel ketolide highly active against respiratory pathogens, abstr. F158, p. 140. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Agouridas, C., A. Bonnefoy, and J. F. Chantot. 1997. Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens. Antimicrob. Agents Chemother. 41:2149-2158.
3. Araujo, F. G., A. A. Khan, T. L. Slifer, A. Bryskier, and J. S. Remington. 1997. The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection. Antimicrob. Agents Chemother. 41:2137-2140.
4. Barry, A. L., P. C. Fuchs, and S. D. Brown. 1997. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilia influenzae. Eur. J. Clin. Microbiol. Infect. Dis. 16:767-769.
5. Bornstein, N., H. Behr, Y. Brun, and J. Fleurette. 1995. In vitro activity of RU 004 on Legionella species, abstr. F166, p. 142. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. Bryskier, A., C. Agouridas, and J. F. Chantot. 1997. Ketolides: new semi-synthetic 14-membered-ring macrolides, p. 39-50. In S. H. Zinner, L. S. Young, J. Acar, and H. C. Neu (ed.), Expanding indications for the new macrolides, azalides, and streptogramins. Marcel Dekker, Inc., New York, N.Y.
7. Dupront, A., D. Coussediere, and B. Lenfant. 1997. Assay technique of HMR 3647 in human plasma, p. 1-56. Hoechst Marion Roussel. Romainville, France.
8. Dupront, A., and B. Lenfant. 1997. Assay technique of HMR 3647 in human plasma. Addendum No. 5: 12 months stability of HMR 3647 in frozen plasma, p. 1-2. Hoechst Marion Roussel, Romainville, France.
9. Edelstein, P. H. 1995. Antimicrobial chemotherapy for Legionnaires' disease: a review. Clin. Infect. Dis. 21:S265-S276.
10. Edelstein, P. H., K. Calarco, and V. K. Yasui. 1984. Antimicrobial therapy of experimentally induced Legionnaires' disease in guinea pigs. Am. Rev. Respir. Dis. 130:849-856.
11. Edelstein, P. H., and M. A. C. Edelstein. 1989. WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages. Antimicrob. Agents Chemother. 33:2132-2136.
12. Edelstein, P. H., and M. A. C. Edelstein. 1991. In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrob. Agents Chemother. 35:180-181.
13. Edelstein, P. H., and M. A. C. Edelstein. 1993. Comparison of three buffers used in the formulation of buffered charcoal yeast extract medium. J. Clin. Microbiol. 31:3329-3330.
14. Edelstein, P. H., M. A. C. Edelstein, and B. Holzknecht. 1992. In vitro activities of fleroxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 36:2387-2391.
15. Edelstein, P. H., M. A. C. Edelstein, K. H. Lehr, and J. Ren. 1996. In-vitro activity of levofloxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. J. Antimicrob. Chemother. 37:117-126.
16. Edelstein, P. H., M. A. C. Edelstein, J. J. Ren, R. Polzer, and R. P. Gladue. 1996. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 40:314-319.
17. Edelstein, P. H., M. A. C. Edelstein, J. Weidenfeld, and M. B. Dorr. 1990. In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 34:2122-2127.
18. Ednie, L. M., S. K. Spangler, M. R. Jacobs, and P. C. Appelbaum. 1997. Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole. Antimicrob. Agents Chemother. 41:1037-1041.
19. Ednie, L. M., S. K. Spangler, M, R. Jacobs, and P. C. Appelbaum. 1997. Susceptibilities of 228 penicillin-and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents. Antimicrob. Agents Chemother. 41:1033-1036.
20. Fang, G.-D., V. L. Yu, and R. M. Vickers. 1989. Disease due to the Legionellaceae (other than Legionella pneumophila). Historical, microbiological, clinical, and epidemiological review. Medicine (Baltimore) 68:116-132.
21. Fitzgeorge, R. B., S. Lever, and A. Baskerville. 1993. A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaires' disease. J. Antimicrob. Chemother. 31(Suppl. E): 171-176.
22. Frean, J. A., L. Arntzen, T. Capper, A. Bryskier, and K. P. Klugman. 1996. In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus. Antimicrob. Agents Chemother. 40:2646-2647.
23. García, I., A. Pascula, S. Ballesta, and E. J. Perea. 1998. Uptake and intracellular activity of HMR 3647 in human phagocytic and nonphagocytic cells, abstr. A-112, p. 35. In Program and abstracts of the 38th interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
24. Havlichek, D., L. Saravolatz, and D. Pohlod. 1987. Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila. Antimicrob. Agents Chemother. 31:1529-1534.
25. Horwitz, M. A., and S. C. Silverstein. 1983. Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin. J. Clin. Investig. 71:15-26.
26. Jamjian, C., D. J. Biedenbach, and R. N. Jones. 1997. In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. Antimicrob. Agents Chemother. 41:454-459.
27. Kitsukawa, K., J. Hara, and A. Saito. 1991. Inhibition of Legionella pneumophila in guinea pig peritoneal macrophages by new quinolone, macrolide and other antimicrobial agents. J. Antimicrob. Chemother. 27:343-353.
28. Lenfant, B., E. Sultan, C. Wable, M. H. Pascual, and B. H. Meyer. 1998. Pharmacokinetics of 800-mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers, abstr. A-49, p. 16. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
29. Martin, S. J., S. L. Pendland, C. Chen, P. C. Schreckenberger, and L. H. Danziger. 1997. In vitro activity of clarithromycin alone and in combination with ciprofloxacin or levofloxacin against Legionella spp.: enhanced effect by the addition of the metabolite 14-hydroxy clarithromycin. Diagn. Microbiol. Infect. Dis. 29:167-171.
30. Rajagopalan-Levasseur, P., E. Dournon, G. Dameron, J.-L. Vilde, and J.-J. Pocidalo. 1990. Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1. Antimicrob. Agents Chemother. 34:1733-1738.
31. Schulin, T., C. B. Wennersten, R. C. J. Moellering, and G. M. Eliopoulos. 1997. In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria. Antimicrob. Agents Chemother. 41:1195-1202.
32. Vazifeh, D., H. Abdelghaffar, and M. T. Labro. 1997. Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. Antimicrob. Agents Chemother. 41: 2099-2107.
33. Vazifeh, D., A. Preira, A. Bryskier, and M. T. Labro. 1998. Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob. Agents Chemother. 42:1944-1951.
34. Vildé, J. L., E. Dournon, and P. Rajagopalan. 1986. Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents. Antimicrob. Agents Chemother. 30:743-748.